Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

BioMarin typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior shows BioMarin experiences moderate volatility around earnings, with an average absolute Day 0 move of 2.13% and a Day +1 move of 2.88%. The Day +1 range averages 7.11%, indicating substantial intraday volatility as investors digest the results and management commentary. Recent quarters have shown mixed directional patterns—the most recent report (August 2026) produced a +2.59% Day 0 move and +3.82% Day +1 move, while the prior quarter (May 2026) saw a +2.59% Day 0 move followed by a -4.00% Day +1 reversal. The largest recent reaction came in February 2026, when the stock declined 1.81% on Day 0 but then traded in a 10.56% range on Day +1. Investors should expect post-earnings moves in the 2-4% range on average, with potential for significantly larger swings depending on guidance updates and commentary around the Amicus integration timeline.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 4.50% (±$2.64) for the November 20 expiration, which is notably higher than the historical average Day 0 move of 2.13% but below the average Day +1 move of 2.88%. This suggests options traders are anticipating above-average volatility for this earnings release, likely reflecting uncertainty around Amicus integration costs, VOXZOGO guidance, and pipeline updates following the BMN 401 discontinuation.

Part 3: What Analysts Are Saying

Analyst sentiment on BioMarin has improved heading into the Q3 report, with the consensus now firmly bullish on the stock's prospects. The current average recommendation stands at 4.43 out of 5.00, up from 4.37 a month ago, reflecting growing confidence in the company's commercial execution and integration progress. The analyst community includes 20 Strong Buy ratings (up from 18 a month ago), zero Moderate Buy ratings (down from 1), 8 Hold ratings (unchanged), and zero Sell or Strong Sell ratings across 28 total recommendations.

The average price target of $89.23 implies 52.5% upside from the current price of $58.51, with a wide range of expectations spanning from a low target of $58.00 to a high of $122.00. This substantial upside potential reflects analyst conviction that BioMarin's rare disease portfolio—particularly VOXZOGO's path to $1 billion in sales—will drive meaningful value creation as integration costs subside and the company realizes projected synergies by 2028.

The strengthening consensus comes despite near-term profitability headwinds, suggesting analysts are looking through integration-related expenses to focus on the company's expanded commercial footprint, pipeline optionality with the new Fabry disease asset, and management's track record of executing on complex rare disease launches. The absence of any Sell ratings and the concentration of Strong Buy recommendations indicate the Street views current levels as an attractive entry point ahead of the anticipated 2028 inflection toward non-GAAP EPS accretion.

Part 4: Technical Picture

BioMarin's technical setup heading into earnings shows improving momentum after a period of consolidation. The Barchart Technical Opinion currently registers an 8% Buy signal, a significant improvement from last week's 40% Sell signal and last month's 8% Sell signal, indicating a sharp reversal in near-term technical sentiment.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal suggests some near-term resistance remains despite the recent improvement in the overall technical opinion
• Medium-term (50% Buy): Neutral-to-positive reading indicates the intermediate trend is stabilizing as the stock works through its consolidation phase
• Long-term (50% Buy): Balanced signal reflects a longer-term trend that remains constructive despite recent volatility

Trend Characteristics: The current trend shows Minimum strength with the Weakest direction, suggesting the recent technical improvement is still in early stages and lacks conviction, which could leave the stock vulnerable to headline risk around the earnings release.

The stock is currently trading at $58.51, positioned above its 5-day ($56.62), 10-day ($56.20), 20-day ($55.81), and 200-day ($58.44) moving averages, but below its 50-day ($60.62) and 100-day ($60.51) moving averages. This configuration indicates the stock has recently broken above its 200-day moving average after testing support in the mid-$50s, but still faces overhead resistance at the 50-day and 100-day levels.

The 52-week range of $49.26 to $70.98 shows the stock is currently trading in the lower half of its annual range, approximately 19% above the low and 17.6% below the high. Key resistance sits at the 50-day moving average around $60.62, which aligns closely with the options market's upper expected move boundary of $61.15. Support appears solid at the 20-day moving average near $55.81, which corresponds to the recent consolidation lows. The technical setup is cautiously supportive heading into earnings—the stock has established a base above its 200-day moving average and short-term momentum is improving, but the weak trend characteristics and proximity to overhead resistance suggest limited room for disappointment. A strong beat with positive guidance could propel the stock through the 50-day resistance toward the $65-70 zone, while a miss or cautious outlook could quickly test support back toward the $55-56 area.